English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/182214
Share/Impact:
Statistics
logo share SHARE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Title

Expansion of allogeneic NK cells with efficient antibody-dependent cell cytotoxicity against multiple tumors

AuthorsSánchez-Martínez, Diego; Allende-Vega, Nerea; Orecchioni, Stefania; Talarico, Giovanna; Cornillon, Amelie; Vo, Dang-Nghiem; Rene, Celine; Lu, Zhao-Yang; Krzywinska, Ewelina; Anel Bernal, Luis Alberto; Gálvez Buerba, Eva Mª ; Pardo, Julián; Robert, Bruno; Martineau, Pierre; Hicheri, Yosr; Bertolini, Francesco; Cartron, Guillaume; Villalba, Martín
KeywordsNK cells
Monoclonal antibodies (mAbs)
Antibody-dependent cell cytotoxicity (ADCC)
Cancer
Issue Date14-Jun-2018
PublisherIvyspring International Publisher
CitationTheranostics 8(14): 3856-3869 (2018)
AbstractMonoclonal antibodies (mAbs) have significantly improved the treatment of certain cancers. However, in general mAbs alone have limited therapeutic activity. One of their main mechanisms of action is to induce antibody-dependent cell-mediated cytotoxicity (ADCC), which is mediated by natural killer (NK) cells. Unfortunately, most cancer patients have severe immune dysfunctions affecting NK activity. This can be circumvented by the injection of allogeneic, expanded NK cells, which is safe. Nevertheless, despite their strong cytolytic potential against different tumors, clinical results have been poor. Methods: We combined allogeneic NK cells and mAbs to improve cancer treatment. We generated expanded NK cells (e-NK) with strong in vitro and in vivo ADCC responses against different tumors and using different therapeutic mAbs, namely rituximab, obinutuzumab, daratumumab, cetuximab and trastuzumab. Results: Remarkably, e-NK cells can be stored frozen and, after thawing, armed with mAbs. They mediate ADCC through degranulation-dependent and -independent mechanisms. Furthermore, they overcome certain anti-apoptotic mechanisms found in leukemic cells. Conclusion: We have established a new protocol for activation/expansion of NK cells with high ADCC activity. The use of mAbs in combination with e-NK cells could potentially improve cancer treatment.
Description6 Figuras
Publisher version (URL)http://dx.doi.org/10.7150/thno.25149
URIhttp://hdl.handle.net/10261/182214
DOI10.7150/thno.25149
E-ISSN1838-7640
Appears in Collections:(ICB) Artículos
Files in This Item:
File Description SizeFormat 
Theranostics 2018_8.pdfPdf editorial1,81 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.